Eskenazi Health has been selected as a recipient of a GI Genius™ intelligent endoscopy module as part of the Medtronic Health Equity Assistance Program for colorectal cancer screening, which launched in February 2022. The new module screening is supported by the American Society for Gastrointestinal Endoscopy and Amazon Web Services.

The GI Genius™ intelligent endoscopy module, authorized by the U.S. Food and Drug Administration in 2021, is the first-to-market, computer-aided polyp detection system powered by artificial intelligence to detect colorectal polyps of varying shapes and sizes automatically in real time which helps diagnose and prevent colorectal cancer. In the first U.S. trial using GI Genius™, results showed a 50% reduction in missed colorectal polyps with AI technology versus standard colonoscopy.

According to the American Cancer Society, certain types of colorectal cancer, when caught early, can have a survival rate (five year) of up to 91%; however, it remains the third most common and third deadliest cancer among adults in the United States.

“This artificial intelligence technology assists endoscopists to enhance their detection of colorectal polyps and therefore reduce the risk of interval colorectal cancer in our patients. We’re thrilled to be able to further support the health of our community with this new technology,” said Hala Fatima, M.D., Gastroenterology section chief at Eskenazi Health.

The American Society for Gastrointestinal Endoscopy led the submission and selection process for this program.